4DMedical Ltd. is a software technology company, which commercializes four-dimensional lung imaging platform called XV Technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2020-08-07. Through its flagship patented XV Technology, the Company enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers its FDA-cleared XV Lung Ventilation Analysis Software (XV LVA), which is a modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS. XV LVAS and CT LVAS reports are prepared using the Company’s software as a service (SaaS) delivery model using existing hospital imaging equipment or the Company's XV Scanner. The company is also focused on artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. In Australia, it provides access to CT LVAS, accelerating the rollout across the I-MED Radiology Network, Integral Diagnostics and Jones Radiology.
Follow-Up Questions
What is 4Dmedical Ltd (FDMDF)'s P/E Ratio?
The P/E ratio of 4Dmedical Ltd is N/A
What is the price performance of FDMDF stock?
The current price of FDMDF is 1.15, it has decreased 0% in the last trading day.
What are the primary business themes or industries for 4Dmedical Ltd?
4Dmedical Ltd belongs to Health Care industry and the sector is Health Care
What is 4Dmedical Ltd market cap?
4Dmedical Ltd's current market cap is $562.7
Is 4Dmedical Ltd a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for 4Dmedical Ltd, including 2 strong buy, 3 buy, 1 hold, 0 sell, and 2 strong sell
